Inhibikase Therapeutics, Inc. in brief
Inhibikase Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Georgia, USA. Its last known market value was $14 M (December 2022); there is no current figure. Milton Werner is its chief executive. Its shares trade under the symbol IQT.F (Frankfurt).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
Inhibikase Therapeutics, Inc. timeline
- 2018
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- 💰Record revenue of $3 millionFY2021, the highest of the 4 years on record.
Events of Inhibikase Therapeutics, Inc. from SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,071 (Jan 2022) · #5,440 (Dec 2022)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- —
- Free cash flow yield
- —
- Net margin
- —
- Operating margin
- —
- Return on equity
- -27.9%
- Liabilities / assets
- 4.6%
- Net debt
- $-9M
- Revenue growth
- +116.7%
- R&D / revenue
- 5238.5%
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-52M | $-48M | — |
| Dec 2024 | — | — | $-29M | $-28M | — |
| Dec 2023 | $0M | +116.7% | $-20M | $-19M | -7319.2% |
| Dec 2022 | $0M | -96.1% | $-18M | $-18M | -15041.7% |
| Dec 2021 | $3M | +342.9% | $-15M | $-15M | -477.1% |
| Dec 2020 | $1M | — | $-3M | $-3M | -407.1% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-28M | $0M | $-28M | $-0.49 | — |
| Dec 2024 | $-19M | $0M | $-19M | $-1.16 | — |
| Dec 2023 | $-18M | $0M | $-18M | $-3.16 | — |
| Dec 2022 | $-17M | $0M | $-18M | $-4.28 | — |
| Dec 2021 | $-14M | $0M | $-14M | $-0.81 | — |
| Dec 2020 | $-1M | — | — | $-0.35 | — |
Quarterly results
Latest quarter to Sep 2026: revenue —, net income $-20M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.
SEC filings
- Nov 10, 202610-QQuarterly report · period to Sep 2026
- Nov 10, 20268-KCurrent reportResults of operations
- Oct 20, 20268-KCurrent reportDirectors or officers changed · Regulation FD disclosure
- Sep 8, 20268-KCurrent reportRegulation FD disclosure
- Aug 26, 20268-KCurrent reportAuditor change
- Aug 11, 202610-QQuarterly report · period to Jun 2026
- Aug 11, 20268-KCurrent reportResults of operations
- Jul 29, 20268-KCurrent reportUnregistered share sale
- Jul 23, 20268-KCurrent reportRegulation FD disclosure
- Jul 14, 20268-KCurrent reportOther events
- Jun 29, 20268-KCurrent reportDirectors or officers changed · Bylaws amended · Shareholder vote
- May 12, 202610-QQuarterly report · period to Mar 2026
Official filings of Inhibikase Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-52 M
- Net income
- $-48 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $181 M
- Total liabilities
- $8 M
- Total equity
- $173 M
As of December-2025
Mutual funds holding Inhibikase Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 3.76 M | $8 M | — | <0.01% | +9.9% | Jun 30, 2026 |
| 🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors | 3.01 M | $6 M | — | <0.01% | +23% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC | 1.32 M | $3 M | — | <0.01% | +25% | Jul 31, 2026 |
| 🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors | 1.11 M | $2 M | — | 0.02% | +34% | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 1.06 M | $2 M | — | <0.01% | +16% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Index FundThe Vanguard Group, Inc. | 547,192 | $1 M | — | <0.01% | +83% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 406,711 | $1 M | — | 0.05% | +51% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 421,326 | $1 M | — | <0.01% | +121% | May 31, 2026 |
| 🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc. | 294,004 | $1 M | — | <0.01% | +25% | Jul 31, 2026 |
| 🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC | 236,794 | $0 M | — | <0.01% | +36% | Jun 30, 2026 |
| 🇺🇸 College Retirement Equities Fund - Total Global Stock AccountTIAA-CREF Investment Management, LLC | 215,750 | $0 M | — | <0.01% | −8.5% | Jun 30, 2026 |
| 🇺🇸 Nuveen Small Cap Blend Index FundTeachers Advisors, LLC | 161,780 | $0 M | — | <0.01% | +27% | Jul 31, 2026 |
| 🇺🇸 JPMorgan Small Cap Value FundJ.P. Morgan Investment Management Inc. | 171,152 | $0 M | — | 0.03% | −5.7% | Jun 30, 2026 |
| 🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC | 169,113 | $0 M | — | 0.02% | +40% | Jun 30, 2026 |
| 🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC | 142,061 | $0 M | — | <0.01% | +34% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 143,459 | $0 M | — | <0.01% | +174% | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 113,097 | $0 M | — | <0.01% | +107% | May 31, 2026 |
| 🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation | 90,100 | $0 M | — | <0.01% | +88% | Jun 30, 2026 |
| 🇺🇸 Vanguard Russell 2000 Value Index FundThe Vanguard Group, Inc. | 75,662 | $0 M | — | 0.01% | +88% | May 31, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 63,298 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC | 57,994 | $0 M | — | <0.01% | +25% | Jul 31, 2026 |
| 🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc. | 56,309 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 52,148 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Select Biotechnology PortfolioFidelity Management & Research Company LLC | 56,270 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Bridge Builder Small/Mid Cap Value FundOLIVE STREET INVESTMENT ADVISERS LLC | 42,523 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 JPMorgan Small Cap Value PortfolioBrighthouse Investment Advisers, LLC | 42,101 | $0 M | — | 0.03% | −14% | Jun 30, 2026 |
| 🇺🇸 Avantis U.S. Small Cap Equity ETFAmerican Century ETF Trust | 47,634 | $0 M | — | <0.01% | new | May 31, 2026 |
| 🇺🇸 Small Cap Index FundThe Variable Annuity Life Insurance Company | 44,328 | $0 M | — | <0.01% | +84% | May 31, 2026 |
| 🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc. | 36,600 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 MetLife Russell 2000 Index PortfolioBrighthouse Investment Advisers, LLC | 36,124 | $0 M | — | <0.01% | −1.1% | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 40,273 | $0 M | — | <0.01% | +33% | May 31, 2026 |
| 🇺🇸 Small Cap Value FundThe Variable Annuity Life Insurance Company | 34,863 | $0 M | — | 0.02% | new | May 31, 2026 |
| 🇺🇸 iShares Russell Small/Mid-Cap Index FundBlackRock Advisors, LLC | 27,096 | $0 M | — | <0.01% | +293% | Jul 31, 2026 |
| 🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC | 28,770 | $0 M | — | <0.01% | +35% | Jun 30, 2026 |
| 🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS | 27,823 | $0 M | — | <0.01% | +36% | Jun 30, 2026 |
| 🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC | 27,600 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 27,404 | $0 M | — | 0.03% | +45% | Jun 30, 2026 |
| 🇺🇸 Small Cap Index TrustJohn Hancock Variable Trust Advisers LLC | 20,052 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc. | 19,063 | $0 M | — | <0.01% | +28% | Jun 30, 2026 |
| 🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC | 18,480 | $0 M | — | <0.01% | +26% | Jun 30, 2026 |
| 🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc. | 18,305 | $0 M | — | <0.01% | +58% | Jun 30, 2026 |
| 🇺🇸 Voya RussellTM Small Cap Index PortfolioVoya Investments, LLC | 15,963 | $0 M | — | <0.01% | +53% | Jun 30, 2026 |
| 🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC | 14,217 | $0 M | — | <0.01% | +107% | Jul 31, 2026 |
| 🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC | 12,924 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc. | 11,504 | $0 M | — | <0.01% | +9.0% | Jul 31, 2026 |
| 🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management | 11,018 | $0 M | — | <0.01% | +78% | Jun 30, 2026 |
| 🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC | 9,682 | $0 M | — | <0.01% | +93% | Jun 30, 2026 |
| 🇺🇸 Voya VACS Index Series SC PortfolioVoya Investments, LLC | 9,323 | $0 M | — | <0.01% | +43% | Jun 30, 2026 |
| 🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS | 8,689 | $0 M | — | <0.01% | no change | Jul 31, 2026 |
| 🇺🇸 Nationwide Fundamental All Cap Equity PortfolioNATIONWIDE FUND ADVISORS | 8,278 | $0 M | — | <0.01% | new | Jul 31, 2026 |
| 🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC | 8,105 | $0 M | — | <0.01% | +124% | Jul 31, 2026 |
| 🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC | 8,555 | $0 M | — | 0.01% | +46% | Jun 30, 2026 |
| 🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC | 7,660 | $0 M | — | <0.01% | +432% | Jun 30, 2026 |
| 🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC | 7,660 | $0 M | — | <0.01% | +432% | Jun 30, 2026 |
| 🇺🇸 Siit Extended Market Index FundSEI INVESTMENTS MANAGEMENT CORPORATION | 7,800 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Vanguard Russell 2000 Growth Index FundThe Vanguard Group, Inc. | 6,942 | $0 M | — | <0.01% | +92% | May 31, 2026 |
| 🇺🇸 Vanguard Russell 3000 Index FundThe Vanguard Group, Inc. | 6,410 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC | 5,345 | $0 M | — | <0.01% | +30% | Jun 30, 2026 |
| 🇺🇸 Strategic Equity Allocation TrustJohn Hancock Variable Trust Advisers LLC | 4,440 | $0 M | — | <0.01% | −49% | Jun 30, 2026 |
| 🇺🇸 ProShares Russell 2000 High Income ETFPROSHARE ADVISORS LLC | 5,044 | $0 M | — | <0.01% | +93% | May 31, 2026 |
| 🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc. | 3,479 | $0 M | — | <0.01% | +71% | Jun 30, 2026 |
| 🇺🇸 ProShares UltraPro Russell2000PROSHARE ADVISORS LLC | 3,987 | $0 M | — | <0.01% | +6.9% | May 31, 2026 |
| 🇺🇸 ProShares Ultra Russell2000PROSHARE ADVISORS LLC | 3,944 | $0 M | — | <0.01% | +5.4% | May 31, 2026 |
| 🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC | 2,749 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 2,425 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Destinations Small-Mid Cap Equity FundBrinker Capital Investments, LLC | 2,165 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P. | 52 | $0 M | — | <0.01% | +108% | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 67 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Inhibikase Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Dennis N. BermanDirector | Option exercise | +21,854 | $1.260 | $28 K | 21,854 | Form 4 |
| filed | RA Capital Healthcare Fund LP10% owner | Otherindirect | -18.03 M | — | — | 6.97 M | Form 4 |
| filed | Amit MunshiDirector | Disposal to the company | -19,089 | — | — | 38,176 | Form 4 |
| filed | Christopher CabellPresident & Head of R&D | Disposal to the company | -338,282 | — | — | 676,564 | Form 4 |
| filed | Vincent AurentzDirector | Disposal to the company | -255,299 | — | — | 510,596 | Form 4 |
| filed | Frank M. Sands10% owner | Buy | +2.07 M | $1.450 | $3.0 M | 13.02 M | Form 4 |
| filed | Amit MunshiDirector | Grant or award | +57,265 | — | — | 57,265 | Form 4 |
| filed | Arvind KushDirector | Buy | +145,000 | $1.370 | $199 K | 145,000 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Inhibikase Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-1.14 reverse split
Fails to deliver
- : 2,441 shares at $1.67
- : 3,955 shares at $1.62
- : 1,495 shares at $1.59
- : 9,082 shares at $1.65
- : 3,776 shares at $1.91
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Inhibikase Therapeutics, Inc. scorecard#
Passes 1 of the 8 checks that could be worked out. Fiscal year 2025.
Valuationnot known
- –P/E below its peers' medianNo market cap.
- –Price to book below its peers' medianNo market cap.
- –Price to sales below its peers' medianNo market cap.
- –Free cash flow yield above 5%No market cap.
- –Earnings yield above the 10-year Treasury yieldNo market cap.
- –The price assumes slower growth than the last three years'No market cap.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-0.49 vs -1.16Diluted EPS -0.49 in fiscal 2025 against -1.16 the year before (report's currency).
- ✗Net income higher than five years earlier-$48 M-$48 M in fiscal 2025 against -$3 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$48 MNet income -$48 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-36.0%-36.0% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities21.7×Current ratio 21.70 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returns0 of 1
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- ✗Share count up no more than 2% in a year314.6%Diluted shares up 314.6% in fiscal 2025.
- –Dividends and buybacks above 3% of the market valueNo market cap.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Inhibikase Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | — | 0−100%— | 0.3+111%100% | 0.1−96.0%100% | 3.1+344%100% | 0.7—100% | |
| Research and development | 30+73.1%— | 17+26.4%— | 14+13.2%5228% | 12+6.0%9750% | 11+1171%366% | 0.9—128% | |
| Selling, general and administrative | 24+107%— | 11+69.0%— | 6.7+8.3%2584% | 6.2−4.5%5037% | 6.5+148%210% | 2.6—376% | |
| Total costs and expenses | 52+81.8%— | 29+40.5%— | 20+11.5%7812% | 18+2.2%14786% | 18+408%576% | 3.5—504% | |
| Operating income | −52—— | −29—— | −20—−7712% | −18—−14686% | −15—−476% | −2.8—−404% | |
| Interest expense and finance costs | — | — | — | — | 0.0−32.2%0.6% | 0.0—4.2% | |
| Net interest income | 3.7+247%— | 1.1+0.8%— | 1.1+1325%407% | 0.1—60.3% | −0.0—−0.6% | — | |
| Income before tax | −0.0—— | −0.0—— | — | — | — | — | |
| Income tax | 0—— | 0—— | — | — | — | — | |
| Net income attributable to shareholders | −48—— | −28—— | −19—−7305% | −18—−14626% | −15—−477% | −2.8—−408% | |
| Earnings per share, basic | -0.49—— | -1.16—— | -3.16r-3.57—— | -4.28r-0.72—— | -0.81—— | -0.35—— | |
| Earnings per share, diluted | -0.49—— | -1.16—— | -3.16r-3.57—— | -4.28r-0.72—— | -0.81—— | -0.35—— | |
| Shares, weighted average (basic) | 98+315%— | 24+293%— | 6.0r5.3+42.7%— | 4.2r25−76.8%— | 18—— | — | |
| Shares, weighted average (diluted) | 98+315%— | 24+293%— | 6.0r5.3+42.7%— | 4.2r25−76.8%— | 18+122%— | 8.2—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 179+83.4%98.7% | 98r57+960%98.9% | 9.2r9.2+28.0%63.4% | 7.2−82.4%28.8% | 41+192%96.0% | 14—94.4% | |
| Short-term investments | 40−3.7%21.8% | 41+905%41.6% | 4.1−74.2%28.2% | 16—63.6% | 0—0.0% | — | |
| Other current assets | 0.3−58.5%0.2% | 0.8+11.8%0.8% | 0.7r0.7+352%5.1% | 0.2−89.1%0.7% | 1.5+2640%3.5% | 0.1—0.4% | |
| Current assets | 180+82.9%99.4% | 98+593%99.8% | 14−41.7%98.0% | 24−42.6%97.7% | 42+187%100% | 15—100% | |
| Property, plant and equipment | 0−100%0.0% | 0.0−35.8%0.0% | 0.1−69.0%0.5% | 0.2—0.9% | 0—0.0% | — | |
| Right-of-use (leased) assets | 0−100%0.0% | 0.1−54.4%0.1% | 0.2−32.4%1.5% | 0.3—1.3% | 0—0.0% | — | |
| Total assets | 181+83.8%100% | 99+580%100% | 15−41.8%100% | 25−41.3%100% | 42+187%100% | 15—100% | |
| Accounts payable | 1.2+22.8%0.6% | 0.9+45.8%1.0% | 0.6−43.8%4.5% | 1.2+5.6%4.6% | 1.1−36.7%2.6% | 1.7—11.6% | |
| Debt due within a year | 0−100%0.0% | 0.1−26.4%0.1% | 0.2+2.9%1.0% | 0.1—0.6% | 0—0.0% | — | |
| Current liabilities | 8.3+122%4.6% | 3.7+8.6%3.8% | 3.4−7.0%23.7% | 3.7−8.9%14.8% | 4.1−14.1%9.5% | 4.7—31.9% | |
| Lease liabilities (non-current) | — | — | 0.1−56.1%0.6% | 0.2—0.8% | — | — | |
| Total liabilities | 8.3+122%4.6% | 3.7+5.8%3.8% | 3.5−9.5%24.3% | 3.9−3.8%15.6% | 4.1−18.9%9.5% | 5.0—33.8% | |
| Retained earnings | −143—−78.7% | −94—−95.8% | −67—−461% | −48—−192% | −30r30−298%−70.2% | 15r−15—102% | |
| Shareholders' equity | 173+82.3%95.4% | 95+764%96.2% | 11−47.8%75.7% | 21−45.2%84.4% | 38+293%90.5% | 9.8—66.2% | |
| Total liabilities and equity | 181+83.8%100% | 99+580%100% | 15−41.8%100% | 25−41.3%100% | 42+187%100% | 15—100% | |
| Shares outstanding | 132+89.9%— | 69+1021%— | 6.2+46.4%— | 4.2r25−83.2%— | 25+150%— | 10—— | |
| Cash-flow statement | |||||||
| Share-based compensation | 15+88.1%— | 8.1+1528%— | 0.5+9.2%192% | 0.5−70.1%371% | 1.5+167%49.4% | 0.6—82.1% | |
| Cash from operating activities | −28—— | −19—— | −18—−6942% | −17—−14056% | −14—−461% | −1.1—−162% | |
| Capital expenditure | −0.0—— | 0—— | −0.0—−5.5% | −0.2—−197% | 0—0.0% | — | |
| Cash from investing activities | 2.1—— | −37−417%— | 12—4475% | −16—−12966% | 0—0.0% | — | |
| Shares issued | 108+4.0%— | 103+1111%— | 8.5—3280% | 0—0.0% | 0−100%0.0% | 0.0—0.7% | |
| Cash from financing activities | 108+4.8%— | 103+1131%— | 8.4—3226% | −0.2−100%−166% | 41+173%1325% | 15—2157% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | — | — | 0—— | 0—— | — | 0—— | 0—— | 0—— | 0*−100%— | 0—— | 0—— | 0—— | 0.0*—100% | |
| Research and development | 46+48.9%— | 15+96.1%— | 13+154%— | 11+3.1%— | 6.4*−11.6%— | 7.6+82.6%— | 5.3+71.4%— | 11+282%— | 7.2*+140%— | 4.2—— | 3.1—— | 2.8—— | 3.0*—300298000% | |
| Selling, general and administrative | 29+29.0%— | 7.2+28.8%— | 7.7+29.4%— | 7.4+40.5%— | 6.8*+18.1%— | 5.6+243%— | 5.9+200%— | 5.2+158%— | 5.7*+309%— | 1.6—— | 2.0—— | 2.0—— | 1.4*—140058700% | |
| Total costs and expenses | 75+46.5%— | 22+74.1%— | 21+94.3%— | 18+22.2%— | 14*+6.6%— | 13+119%— | 11+114%— | 15+205%— | 13*+194%— | 5.8—— | 5.1—— | 4.8—— | 4.4*—440356700% | |
| Operating income | −75—— | −22—— | −21—— | −18—— | −14*—— | −13—— | −11—— | −15—— | −13*—— | −5.8—— | −5.1—— | −4.8—— | −4.4*—−440356600% | |
| Net interest income | 5.7+64.9%— | 1.8+110%— | 1.5+59.2%— | 1.5+58.9%— | 1.0*+30.8%— | 0.8+1596%— | 0.9+908%— | 0.9+593%— | 0.8*+253%— | 0.0—— | 0.1—— | 0.1—— | 0.2*—22562600% | |
| Income tax | — | — | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*—— | 0—— | 0—— | 0—— | — | |
| Net income attributable to shareholders | −69—— | −20—— | −20—— | −16—— | −13*—— | −12—— | −9.9—— | −14—— | −12*—— | −5.8—— | −5.0—— | −4.6—— | −4.2*—−417794000% | |
| Earnings per share, basic | — | -0.10—— | -0.11—— | -0.10—— | — | -0.13—— | -0.11—— | -0.15—— | — | -0.65—— | -0.66—— | -0.73—— | — | |
| Earnings per share, diluted | — | -0.10—— | -0.11—— | -0.10—— | — | -0.13—— | -0.11—— | -0.15—— | — | -0.65—— | -0.66—— | -0.73—— | — | |
| Shares, weighted average (basic) | 197+119%— | 197+119%— | 175+93.9%— | 172+92.4%— | — | 90+914%— | 90+1094%— | 90+1312%— | — | 8.9—— | 7.5—— | 6.3—— | — | |
| Shares, weighted average (diluted) | 197+119%— | 197+119%— | 175+93.9%— | 172+92.4%— | — | 90+914%— | 90+1094%— | 90+1312%— | — | 8.9—— | 7.5—— | 6.3—— | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 52—25.6% | 52+35.1%25.6% | 31−59.9%19.1% | 50−32.5%28.6% | 179+83.4%98.7% | 38+4090%48.1% | 78+2419%87.5% | 73+3021%77.9% | 98r57+960%98.9% | 0.9—20.9% | 3.1—35.0% | 2.4—21.3% | 9.2r9.2—63.4% | |
| Short-term investments | 142—70.2% | 142+263%70.2% | 128+1188%78.1% | 121+512%69.7% | 40−3.7%21.8% | 39+1576%49.1% | 9.9+104%11.2% | 20+167%20.9% | 41+905%41.6% | 2.3—53.2% | 4.9—55.0% | 7.4—66.8% | 4.1—28.2% | |
| Other current assets | 1.4—0.7% | 1.4+128%0.7% | 0.9+36.8%0.6% | 1.3+38.7%0.7% | 0.3−58.5%0.2% | 0.6+120%0.8% | 0.7+91.5%0.8% | 0.9+9.5%1.0% | 0.8+11.8%0.8% | 0.3—6.4% | 0.4—4.0% | 0.9—7.7% | 0.7r0.7—5.1% | |
| Current assets | 199—98.5% | 199+153%98.5% | 162+82.8%99.2% | 172+82.8%99.3% | 180+82.9%99.4% | 79+1774%98.7% | 89+932%99.9% | 94+771%99.9% | 98+593%99.8% | 4.2—95.7% | 8.6—97.5% | 11—97.6% | 14—98.0% | |
| Property, plant and equipment | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0.0−60.7%0.0% | 0.0−28.4%0.1% | 0.0−35.8%0.0% | 0.1—1.2% | 0.1—0.7% | 0.1—0.6% | 0.1—0.5% | |
| Right-of-use (leased) assets | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0.0−78.7%0.0% | 0.1−64.5%0.1% | 0.1−54.4%0.1% | 0.1—3.0% | 0.2—1.9% | 0.2—1.7% | 0.2—1.5% | |
| Total assets | 202—100% | 202+153%100% | 164+84.1%100% | 173+83.8%100% | 181+83.8%100% | 80+1719%100% | 89+907%100% | 94+752%100% | 99+580%100% | 4.4—100% | 8.8—100% | 11—100% | 15—100% | |
| Accounts payable | 0.9—0.5% | 0.9+52.8%0.5% | 1.0−63.3%0.6% | 1.6−6.2%0.9% | 1.2+22.8%0.6% | 0.6−75.5%0.8% | 2.7+102%3.0% | 1.7+30.8%1.8% | 0.9+45.8%1.0% | 2.5—57.8% | 1.3—15.2% | 1.3—11.7% | 0.6—4.5% | |
| Debt due within a year | — | — | — | — | 0−100%0.0% | 0−100%0.0% | 0.0−75.1%0.0% | 0.1−50.5%0.1% | 0.1−26.4%0.1% | 0.1—3.3% | 0.2—1.7% | 0.2—1.4% | 0.2—1.0% | |
| Current liabilities | 13—6.4% | 13+93.5%6.4% | 10+16.6%6.3% | 5.7−33.2%3.3% | 8.3+122%4.6% | 6.7+36.5%8.4% | 8.8+138%9.9% | 8.6+102%9.1% | 3.7+8.6%3.8% | 4.9—112% | 3.7—42.0% | 4.2—38.2% | 3.4—23.7% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | — | — | — | 0.0—0.3% | 0.1—0.5% | 0.1—0.6% | |
| Total liabilities | 13—6.4% | 13+93.5%6.4% | 10+16.6%6.3% | 5.7−33.2%3.3% | 8.3+122%4.6% | 6.7+36.5%8.4% | 8.8+136%9.9% | 8.6+99.2%9.1% | 3.7+5.8%3.8% | 4.9—112% | 3.7—42.3% | 4.3—38.8% | 3.5—24.3% | |
| Retained earnings | −199—−98.7% | −199—−98.7% | −179—−109% | −159—−91.8% | −143—−78.7% | −130—−163% | −118—−133% | −108—−115% | −94—−95.8% | −82—−1880% | −77—−867% | −72—−646% | −67—−461% | |
| Shareholders' equity | 189—93.6% | 189+159%93.6% | 153+91.5%93.7% | 168+95.5%96.7% | 173+82.3%95.4% | 73—91.6% | 80+1471%90.1% | 86+1165%90.9% | 95+764%96.2% | −0.5—−12.1% | 5.1—57.7% | 6.8—61.2% | 11—75.7% | |
| Total liabilities and equity | 202—100% | 202+153%100% | 164+84.1%100% | 173+83.8%100% | 181+83.8%100% | 80+1719%100% | 89+907%100% | 94+752%100% | 99+580%100% | 4.4—100% | 8.8—100% | 11—100% | 15—100% | |
| Shares outstanding | 140—— | 140+87.5%— | 132+77.2%— | 132+77.6%— | 132+89.9%— | 75+902%— | 75+933%— | 74+1048%— | 69+1021%— | 7.5—— | 7.2—— | 6.5—— | 6.2—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 21+12.2%— | 5.5+22.2%— | 5.3+27.0%— | 5.6+172%— | 4.5*−42.7%— | 4.5+2957%— | 4.2+13611%— | 2.0+3722%— | 7.9*+6369%— | 0.1—— | 0.0—— | 0.1—— | 0.1*—12224900% | |
| Cash from operating activities | −49—— | −17*—— | −12*—— | −12—— | −7.5*—— | −11*—— | −5.6*—— | −4.1—— | −5.3*—— | −4.9*—— | −5.1*—— | −3.9—— | −3.4*—−344243100% | |
| Capital expenditure | 0—— | 0*—— | 0*—— | 0—— | 0*—— | 0*—— | 0*—— | −0.0—— | 0*—— | 0*—— | 0*—— | 0—— | 0*—0.0% | |
| Cash from investing activities | −99—— | −13*—— | −5.9*−160%— | −80−482%— | −0.1*—— | −29*−1238%— | 9.8*+287%— | 21—— | −39*—— | 2.5*—— | 2.5*—— | −3.3—— | −2.1*—−211559500% | |
| Shares issued | 160+60.1%— | 49*—— | 0*−100%— | 2.9—— | 108*+8.0%— | 0*−100%— | 0.0*−100.0%— | 0−100%— | 100*+22053984%— | 0.2*—— | 3.2*—— | 0.4—— | 0.0*—45200% | |
| Cash from financing activities | 162+62.6%— | 50*—— | −0.0*−146%— | 2.9—— | 109*+8.9%— | −0.1*−174%— | 0.0*−99.0%— | 0−100%— | 100*—— | 0.2*—— | 3.2*—— | 0.4—— | −0.1*—−13810400% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Executive pay at Inhibikase Therapeutics, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Mark Iwicki, Milton Werner | $30.6 M | $29.7 M | $6.5 M | $161 |
| 2024Milton Werner | $8.0 M | $7.6 M | $790 K | $256 |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Inhibikase Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
- Auditor changedFiling
Auditor changed 1 · Directors and officers 6 · Material agreement 3 · Agreement ended 1 · Unregistered share sale 2 · Bylaws or fiscal year changed 2 · Shareholder vote 3 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Auditor changed | 8-K | |
| Results announced | 8-K | |
| Unregistered share sale | 8-K | |
| Directors and officersBylaws or fiscal year changedShareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Directors and officersMaterial agreementUnregistered share sale | 8-K | |
| Directors and officers | 8-K | |
| Bylaws or fiscal year changedShareholder vote | 8-K | |
| Agreement ended | 8-K | |
| Directors and officersMaterial agreement | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Nov 10, 2026
Acquisitions and funding#
1 acquisitions, $7 M paid where reported
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| CorHepta Pharmaceuticals | Feb 2025 | — | $7 M | — | Annual report |
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Jan 2023 | $4 M | Private placement after listing | $2 to $10 million | 1 | options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
H-1B hiring at Inhibikase Therapeutics, Inc.#
1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $212 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Associate Director, Clinical Operations (00108024)Natural Sciences Managers | 1 | $212 K |
Where: New York, NY 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Inhibikase Therapeutics Inc
How Inhibikase Therapeutics, Inc. compares in Biotechnology
- Revenue growth116.7% · higher than 84% of 438
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Inhibikase Therapeutics, Inc.🇺🇸 | $14 M | — | — | +116.7% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Dec 25, 2022 (last known)
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Profile updated:
- Nov 16, 2026
Figures from SEC filing, value.today research; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Inhibikase Therapeutics, Inc.? Verify and update this profile — free
Show Inhibikase Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.